Ellison Douglas T 4

What Happened
Douglas T. Ellison, Chief Commercial Officer of Mobia Medical, was granted a derivative award covering 193,940 shares on May 7, 2026. The Form 4 reports the transaction at $0.00 per share (total reported value $0). This was a grant/award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-05-07
• Filing date (Form 4): 2026-05-11 (filed within the SEC’s 2-business-day window)
• Security/amount: Derivative award covering 193,940 shares, reported at $0.00 per share
• Shares owned after transaction: Not specified in this filing
• Footnote: The award is a stock option that vests 25% on May 7, 2027, then in 36 substantially equal monthly installments thereafter (per footnote F1)
• Transaction type code: A = Grant/Award (derivative)

Context
This filing documents a compensation grant (stock option award) rather than an outright purchase or sale. The award vests over time per the footnote; it does not indicate any immediate sale or exercise. For investors, grants are commonly used for executive compensation and do not by themselves signal whether the insider believes the stock will move up or down.